Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Public ClinicalTrials.gov record NCT03687242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-Month Phase 2 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Study identification
- NCT ID
- NCT03687242
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Spruce Biosciences
- Industry
- Enrollment
- 11 participants
Conditions and interventions
Conditions
Interventions
- SPR001 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 5, 2018
- Primary completion
- Jul 7, 2019
- Completion
- Aug 8, 2019
- Last update posted
- Mar 31, 2025
2018 – 2019
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Spruce Biosciences Clinical Site | Orange | California | 92868 | — |
| Spruce Biosciences Clinical Site | San Diego | California | 92123 | — |
| Spruce Biosciences Clinical Site | Atlanta | Georgia | 30046 | — |
| Spruce Biosciences Clinical Site | Indianapolis | Indiana | 46202 | — |
| Spruce Biosciences Clinical Site | Ann Arbor | Michigan | 48109 | — |
| Spruce Biosciences Clinical Site | Minneapolis | Minnesota | 55414 | — |
| Spruce Biosciences Clinical Site | Las Vegas | Nevada | 89148 | — |
| Spruce Biosciences Clinical Site | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03687242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2025 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03687242 live on ClinicalTrials.gov.